Clinical Research Directory

Inclusion Criteria: * Patients with histologically/cytologically stage IIIB, IIIC, IV non-squamous Non-Small Cell Lung Cancer (NSCLC) * PD-L1 TPS\<1% * Life expectancy more than 3 months * Without EGFR-sensitive mutation (19Exon del/21Exon L858R), ALK, ROS1 gene rearrangement or fusion * Has no prior systemic therapy; (chemotherapy and/or radiotherapy is allowed as part of neoadjuvant/adjuvant therapy. Patients who have had recurrence or metastasis for more than 6 months from the end of neoadjuvant/adjuvant treatment would be enrolled) * ECOG score 0-1 * Patients must have at least one measurable lesion according to RECIST 1.1 * Has adequate organ function * Agree to provide tumour tissue samples for biomarker exploration (including but not limited to PD-L1 IHC or NGS testing) * Voluntarily sign a written informed consent form Exclusion Criteria: * Histological examination with Small Cell Lung Cancer or squamous Non-Small Cell Lung Cancer * With active central nervous system (CNS) metastases confirmed by CT or MRI * With other malignancy within 3 years before enrollment * With severe infections within 4 weeks of the first dose of study treatment * Women who are pregnant or lactating * History of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonia requiring hormone therapy * History of myocarditis, cardiomyopathy, and malignant arrhythmia * Tumor compresses important surrounding organs (such as the esophagus) with accompanying symptoms, compressing the superior vena cava or invading the mediastinal vessels, heart, etc. * Risk of bleeding, major hemoptysis, or with history of coagulation dysfunction * Active autoimmune diseases that require systematic treatment within 2 years before enrollment * History of Human Immunodeficiency Virus (HIV) * With active hepatitis B infection * With uncontrollable pleural effusion, pericardial effusion, or ascites that require repeated drainage